A customer in italy notified biomérieux of obtaining non reproducible results when testing a patient's samples using vidas rub igg ii 60 tests (ref.30221, batch 1008940030, expiry date 01-sep-2022) on their vidas 3 (serial number vn03643) compared to another batch.Patient sample id (b)(6): positive result on 22-dec-2021 using vidas rub igg ii 60 tests batch 1008851780 : 17 iu/ml.The patient¿s history showed numerous negative results for anti-rubella igg since (b)(6) 2021.Equivocal result from retest of the same sample on (b)(6) 2021 using vidas rub igg ii 60 tests batch 1008940030: 10 iu/ml and 12 iu/ml.The anti-rubella virus igm tested negative for this sample.Patient sample id (b)(6) sample received in (b)(6) 2020, stored frozen: negative result obtained on (b)(6) 2021 using vidas rub igg ii 60 tests batch 1008940030: 0 iu/ml.It is to be noted that these results were preceded by a valid calibration on (b)(6) 2021 and on (b)(6) 2021 for batch 1008851780 and on (b)(6) 2021 for batch 1008940030.No further information about patient¿s clinical context were available.It was reported that there was no patient harm.Patient results were not affected, nor was there any delay in reporting them.No wrong result was communicated to the physician.
|
An internal investigation was performed.Investigation results.Device history record.There was no capa nor any non-conformity on vidas rub igg ii (ref.30221) linked with customer¿s complaint.Complaint analysis.Up to now, no other complaint for a similar issue was recorded on vidas rub igg ii (ref.30221) lot 1008940030.Test/analysis performed.No customer sample was returned and therefore no sample was available for investigation.Control charts analysis.The complaints laboratory analyzed the results of five internal samples (targets 17.9 - 11.5 -15.3 ¿ 7.32 and 4.79 ui/ml) using six different lots including vidas rub igg ii (ref.30221) lots 1008851780 and 1008940030 mentioned by the customer.The analysis of the control charts showed that all results are within specifications.Customer¿s lot is in the trend of the other lots.Tests performed by complaint laboratory.The complaint laboratory tested four internal samples (targets 17.9 - 11.5 -15.3 and 7.32 ui/ml) using retain kits of vidas rub igg ii (ref.30221) customer¿s lot 1008851780 and lot 1008940030.All the results obtained were within specifications, and similar between the two lots.No significant difference of activity was observed between the two lots compared to those observed before the batch release.Support instrument analysis.Support instrument analysis checked the ml2 logs.No instrument issue was detected.Root cause analysis and conclusion.The complaints laboratory did not reproduce the issue observed by the customer when testing internal samples.The complaints laboratory performed tests on four internal samples, using retain kits of vidas rub igg ii (ref.30221) lots 1008851780 and 1008940030.All sample results were within their expected specifications and similar between the two lots.There was no drift of the customer¿s lot since its release.The root cause has not been identified.Without customer¿s returned samples, the investigation could not be further pursued.According to the investigation above, vidas rub igg ii lots 1008851780 and 1008940030 are still within their expected performances.
|